- Programme
- Thursday
DAY 2 — THURSDAY 2ND JULY 2026
Day 2
Thursday
2nd July 2026
DAY 2 — THURSDAY 2ND JULY 2026
8:00–9:00
Welcome back & coffee
8:15–8:45
Breakfast with the Expert – Sponsored Breakout Sessions
See dedicated Breakout Sessions section ↓
JOURNAL CLUB — CRITICAL READING OF RECENT KEY PUBLICATIONS
Chair: Massi di Pietro
9:00–10:00
Interactive session will take a deep dive into the design, methodology, strengths and limitations of a selection of recent high-impact studies shaping the diagnosis, surveillance, and treatment of Barrett’s oesophagus and early neoplasia. These studies challenge well established clinical practices, should we implement their findings?
9:00–9:15
Biomarker risk stratification to make surveillance work: Deconstructing the NHS Pilot and DELTA Trial.
This talk will critically review recent advances in population-level screening for Barrett’s oesophagus, focusing on findings from the NHS pilot programme and the DELTA trial. It will discuss study design, outcomes, and implications for early detection of oesophageal adenocarcinoma, including screening tools and risk stratification models. Are we ready to implement emerging screening tools, risk stratification models, and real-world feasibility within a public healthcare system?
This talk will critically review recent advances in population-level screening for Barrett’s oesophagus, focusing on findings from the NHS pilot programme and the DELTA trial. It will discuss study design, outcomes, and implications for early detection of oesophageal adenocarcinoma, including screening tools and risk stratification models. Are we ready to implement emerging screening tools, risk stratification models, and real-world feasibility within a public healthcare system?
Nastazja Pilonis
9:15–9:30
Endoscopy surveillance for Barrett's Oesophagus under the spotlight: Deconstructing the BOSS Trial.
The largest randomized study on endoscopic surveillance in Barrett’s oesophagus prompts reconsideration of current surveillance strategiess. We will critically review the trial design, findings, and implications for cancer detection, patient outcomes, and resource use. Does the BOSS trial show that surveillance itself is ineffective or just us not being able to make it work?.
The largest randomized study on endoscopic surveillance in Barrett’s oesophagus prompts reconsideration of current surveillance strategiess. We will critically review the trial design, findings, and implications for cancer detection, patient outcomes, and resource use. Does the BOSS trial show that surveillance itself is ineffective or just us not being able to make it work?.
Yannick Derwa
9:30–9:45
Endoscopic treatment for high-Risk T1a and T1b Adenocarcinoma: Deconstructing the CONGRESS Trial
This UK based study, focusing on endoscopic therapy for high-risk T1a and T1b oesophageal adenocarcinoma, challenges well established clinical practice. This talk will examine the study’s methodology, patient selection and outcomes . Does it provide enough evidence to change current clinical guidelines?.
This UK based study, focusing on endoscopic therapy for high-risk T1a and T1b oesophageal adenocarcinoma, challenges well established clinical practice. This talk will examine the study’s methodology, patient selection and outcomes . Does it provide enough evidence to change current clinical guidelines?.
Roos Pouw
9:45–10:00
Q&A
10:00–10:30
coffee break & networking
BARRETT'S SURVEILLANCE DEBATE: ABANDON OR EVOLVE?
Chair: Yannick Derwa
10:30–10:45
End surveillance now: The evidence says enough.
Massi di Pietro
10:45–11:00
Switch It Up: Making surveillance work with non-endoscopy tools.
Vani Konda
11:00–11:15
Discussion
UPPER GI THERAPEUTIC ENDOSCOPY. PRACTICAL IMAGE & VIDEO SESSION
Chair: Wouter Nagengast & Henna Söderström
11:15–11:30
How to perform an Oesophageal EMR. Tips & Tricks and how to avoid mistakes.
Nastazja Pilonis
11:30–11:45
Principles and strategies on how to perform an Upper GI ESD. Tips & Tricks and how to avoid mistakes.
Mo Abdelrahim
11:45–12:00
Decoding EMR/ESD histopathology reports: A guide for endoscopists.
Sindhu Menon
12:00–12:15
Q&A
BARRETT'S TREATMENT DEBATE: SHOULD ESD REPLACE EMR FOR EARLY NEOPLASIA RESECTION?
Chair: Roos Pouw
12:15–12:30
Yes - Go Big or Go Home: Why ESD should replace EMR.
Alanna Ebigbo
12:30–12:45
No - EMR Endures: proven, practical, and here to stay.
Julia Gauci
12:45–13:00
Discussion
13:00–14:00
lunch break & networking
SOME OF THE CURRENT CONTROVERSIES IN BARRETT'S ENDOTHERAPY
Chair: Vani Konda & Mário Dinis-Ribeiro
14:00–14:15
The risk of overtreatment in Barrett's Endotherapy: Often less is more – Knowing when to hold back may be the best clinical decision.
Wouter Nagengast
14:15–14:30
Low Grade Dysplasia (LGD) in the real world beyond the SURF Trial: True Dysplasia or Overdiagnosis? Ablation or Follow up?
Massi di Pietro
14:30–14:45
Pushing the boundaries: endoscopic management of pT1b adenocarcinoma - Is there still a role for surgery?
Henna Söderström
14:45–15:00
NICE Guidelines recommend considering radiotherapy with/without chemotherapy for high risk T1b oesophageal adenocarcinoma after EMR/ESD – Supporting evidence and current real-world practice.
Eleanor James
15:00–15:15
Q&A
BARRETT'S POST-ENDOTHERAPY FOLLOW-UP DEBATE
Chair: Leo Alexandre
15:15–15:30
Yes - Time to let go: Discharge after proven success. And I'll tell you when.
Mário Dinis-Ribeiro
15:30–15:45
No - Don't drop the guard: Follow-up should continue. And I'll tell you how.
Elizabeth Ratcliffe
15:45–16:00
Discussion
16:00–16:30
tea break & networking
UGI MDT PANEL REAL CASE DISCUSSIONS
UGI MDT Chair: James Catton
16:30–17:30
UGI MDT Panel — Mário Dinis-Ribeiro, Yutaro Higashi, Eleanor James, Sindhu Menon, Massi di Pietro, Yuto Shimamura and Henna Söderström